1LBA Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptorpositive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial

Publication date: April 2018
Source:European Journal of Cancer, Volume 92, Supplement 3
Author(s): N. Harbeck, R. Villanueva Vázquez, D. Tripathy, Y. Lu, M. De Laurentiis, S. Kümmel, D. Taylor, A. Bardia, S. Hurvitz, L. Chow, S. Im, F. Franke, G. Hughes, M. Miller, O. Kong, D. Chandiwana, M. Colleoni




https://ift.tt/2GUYzhA